“A Cost-Effectiveness Analysis of Sotorasib As Second-Line Treatment for Patients With KRAS-G12C-Mutated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Switzerland”. Swiss Medical Weekly 155, no. 1 (January 6, 2025): 3777. Accessed October 23, 2025. https://www.smw.ch/index.php/smw/article/view/3777.